Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Toro

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 1, 2025
Evolving Concept of Value in Health Economics and Outcomes Research: Emerging Tools for Innovation and Access to Cell and Gene Therapies for Rare DiseasesWalter Toro, Min Yang, Anish Patel, et al.
Neurology and Therapy|July 7, 2025
Early Intervention and Speed-to-Effect in Spinal Muscular Atrophy Type 1 Following Onasemnogene Abeparvovec Gene Replacement Therapy: Results of aPost-Hoc Analysis of Pooled Clinical Study DataWalter Toro, Sandra P Reyna, Shannon Ritter, et al.
Advances in Therapy|March 21, 2022
Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular AtrophyMin Yang, Hiroyuki Awano, Satoru Tanaka, et al.
Journal of Market Access & Health Policy|October 31, 2017
Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016Julia I Drake, Juan Carlos Trujillo de Hart, Clara Monleón, et al.
Orphanet Journal of Rare Diseases|December 31, 2024
Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysisAnish Patel, Walter Toro, Min Yang, et al.
Journal of Medical Economics|December 6, 2024
Cost-utility analysis of newborn screening for spinal muscular atrophy in JapanAkira Hata, Akihito Uda, Satoru Tanaka, et al.
Advances in Therapy|September 30, 2023
Patient and Caregiver Outcomes After Onasemnogene Abeparvovec Treatment: Findings from the Cure SMA 2021 Membership SurveyWalter Toro, Min Yang, Mihaela Georgieva, et al.
Plos One|October 21, 2024
Treatment preferences in spinal muscular atrophy: A swing weighting study for caregivers of patients with SMA types 1 and 2Anish Patel, Walter Toro, Siobhan Bourke, et al.
Advances in Therapy|October 29, 2021
Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database AnalysisMarjolaine Gauthier-Loiselle, Martin Cloutier, Walter Toro, et al.
Advances in Therapy|August 16, 2023
Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database AnalysisWalter Toro, Min Yang, Mihaela Georgieva, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 1, 2025
Evolving Concept of Value in Health Economics and Outcomes Research: Emerging Tools for Innovation and Access to Cell and Gene Therapies for Rare DiseasesWalter Toro, Min Yang, Anish Patel, et al.
Neurology and Therapy|July 7, 2025
Early Intervention and Speed-to-Effect in Spinal Muscular Atrophy Type 1 Following Onasemnogene Abeparvovec Gene Replacement Therapy: Results of aPost-Hoc Analysis of Pooled Clinical Study DataWalter Toro, Sandra P Reyna, Shannon Ritter, et al.
Advances in Therapy|March 21, 2022
Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular AtrophyMin Yang, Hiroyuki Awano, Satoru Tanaka, et al.
Journal of Market Access & Health Policy|October 31, 2017
Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016Julia I Drake, Juan Carlos Trujillo de Hart, Clara Monleón, et al.
Orphanet Journal of Rare Diseases|December 31, 2024
Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysisAnish Patel, Walter Toro, Min Yang, et al.
Journal of Medical Economics|December 6, 2024
Cost-utility analysis of newborn screening for spinal muscular atrophy in JapanAkira Hata, Akihito Uda, Satoru Tanaka, et al.
Advances in Therapy|September 30, 2023
Patient and Caregiver Outcomes After Onasemnogene Abeparvovec Treatment: Findings from the Cure SMA 2021 Membership SurveyWalter Toro, Min Yang, Mihaela Georgieva, et al.
Plos One|October 21, 2024
Treatment preferences in spinal muscular atrophy: A swing weighting study for caregivers of patients with SMA types 1 and 2Anish Patel, Walter Toro, Siobhan Bourke, et al.
Advances in Therapy|October 29, 2021
Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database AnalysisMarjolaine Gauthier-Loiselle, Martin Cloutier, Walter Toro, et al.
Advances in Therapy|August 16, 2023
Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database AnalysisWalter Toro, Min Yang, Mihaela Georgieva, et al.
Pageof 2